Jim is a seasoned executive with significant experience in the BioPharmaceutical, Life Sciences, Medical Device, Diagnostics and Pharma services industries. Over the course of his career, Jim has occupied successful CEO, Director, and Executive positions in companies throughout North America, Europe, and Asia, including at Dendrite International, Inc., GlaxoSmithKline PLC, the Isuta Holdings Group of companies, Baxter and other companies. Jim previously served on over 30 Board of Director roles including several public and private companies along with the Advisory Board of Marshall University School of Business since 2013 and the board of North Carolina Biotechnology Center as a member since 2017.
Jim formerly served as President and CEO of BioAgilytix, a leading provider of contract bioanalytical testing services with specialisation in bioanalysis, driving industry leading customer satisfaction and supporting industry experts in delivering innovative solutions for clients across the pharmaceutical and biotech industries.
During his time as CEO of BioAgilytix the company was recognised by the Inc. 5000 list of Fastest Growing Companies for 7 years between 2013 and 2020. The company also boasted award-winning customer service and enjoyed one the highest employee retention rates in the industry.
Jim has completed more than 40 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements and has now transitioned to funding and working with Private Equity and Venture backed companies to further their success.
Jim received a B.B.A. at Marshall University, an M.B.A. at the University of New Haven and an Advanced Management Degree at The Wharton School at The University of Pennsylvania.